Advancing cancer immunotherapy: a vision for the field

Affiliations

¹ Department of Pathology, Leiden University Medical Centre, Albinusdreef, 2333 ZA, Leiden, The Netherlands. n.f.de_miranda@lumc.nl.
² Biocenter, Institute of Bioinformatics, Medical University of Innsbruck, Innrain, 6020, Innsbruck, Austria. zlatko.trajanoski@i-med.ac.at.

Editorial

Noel F C C de Miranda et al. Genome Med. 2019.

. 2019 Jul 29;11(1):51.

doi: 10.1186/s13073-019-0662-6.

¹ Department of Pathology, Leiden University Medical Centre, Albinusdreef, 2333 ZA, Leiden, The Netherlands. n.f.de_miranda@lumc.nl.
² Biocenter, Institute of Bioinformatics, Medical University of Innsbruck, Innrain, 6020, Innsbruck, Austria. zlatko.trajanoski@i-med.ac.at.

No abstract available

Conflict of interest statement

The authors declare that they have no competing interests.

1. Haslam A, Prasad V. Estimation of the percentage of US patients with cancer who are eligible for and respond to checkpoint inhibitor immunotherapy drugs. JAMA Netw Open. 2019;2:e192535. doi: 10.1001/jamanetworkopen.2019.2535. - DOI - PMC - PubMed
1. Havel JJ, Chowell D, Chan TA. The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy. Nat Rev Cancer. 2019;19:133–150. doi: 10.1038/s41568-019-0116-x. - DOI - PMC - PubMed
1. Mariathasan S, Turley SJ, Nickles D, Castiglioni A, Yuen K, Wang Y, et al. TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature. 2018;554:544–548. doi: 10.1038/nature25501. - DOI - PMC - PubMed
1. Chen DS, Mellman I. Elements of cancer immunity and the cancer-immune set point. Nature. 2017;541:321–330. doi: 10.1038/nature21349. - DOI - PubMed
1. Dijkstra KK, Cattaneo CM, Weeber F, Chalabi M, van de Haar J, Fanchi LF, et al. Generation of tumor-reactive T cells by co-culture of peripheral blood lymphocytes and tumor organoids. Cell. 2018;174:1586–1598. doi: 10.1016/j.cell.2018.07.009. - DOI - PMC - PubMed